PLANO, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, Diron Smith, Vice President and Interim Chief Financial Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development & Investor Relations, are scheduled to participate at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 1:30 p.m. ET.
A live webcast of the presentation will be available through Integer’s investor relations website at investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: | |
| Andrew Senn | Kelly Butler | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$132.17 |
| Daily Change: | -0.35 -0.26 |
| Daily Volume: | 109,505 |
| Market Cap: | US$4.430B |
October 24, 2024 September 23, 2024 August 22, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
